New York investment firm Altitude Investment Management on Thursday announced a USD2.4m strategic investment in EMMAC Life Sciences Limited.
This is its first investment in a European cannabis company.
Headquartered in the UK, EMMAC combines the latest science and research with cutting-edge cultivation, extraction and production.
Altitude's participation is part of a GBP11m financing, which will be used by EMMAC to close pending acquisitions as well as support collaborative research efforts focused on medical cannabis.
Through the financing, EMMAC will import medical cannabis into the UK and manufacture EU GMP products. It has established a research collaboration with Imperial College London to investigate cannabis-based medicinal products designed to directly benefit patients. The initial focus will be research on therapeutic products for chronic pain, spasticity and cancer.
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study